IntelliGEN® is an NGS "hot-spot" panel that contains a single pool of 207 primer pairs used to perform multiplex PCR for preparation of amplicon libraries from genomic "hot-spot" regions frequently mutated in human cancer genes. It covers ~2,600 COSMIC mutations within 50 common oncogenes and tumor suppressor genes.
Different cancer types
Non-Small-Cell Lung Cancer (NSCLC)
Formalin-fixed, paraffin-embedded (FFPE) tissue block or slides, bone marrow, fine needle aspirate (FNA), solid tumor (excision, core, FNA, or endoscopic biopsies).
Five to ten unstained slides at 10-μM and one matching H&E-stained slide or formalin-fixed, paraffin-embedded tissue block, 1 to 2 mL bone marrow, 5 to10 mL FNA.
1 mL bone marrow; FNA requires sufficient cells for DNA extraction
Slides, blocks, lavender-top (EDTA) tube, green-top (sodium heparin) tube, FNA in RPMI or CytoLyt® container
Submit at room temperature. Indicate date and time of collection on test request form. Bone marrow specimens should arrive in the laboratory within 48 hours of collection.Fixative should be neutral-buffered formalin. For solid tumor metastatic bone samples, submit a nondecalcified FFPE sample. Decalcified bone biopsies are not acceptable sample types for this test.
A copy of the original pathology report is required for testing. If a pathology report is not received with the sample, testing will be delayed. Please direct any questions regarding this test to customer service at 800-345-4363.
Formalin-fixed, paraffin-embedded (FFPE) tissue block or slides, bone marrow, fine needle aspirate (FNA), solid tumor (excision, core, FNA, or endoscopic biopsies) formalin-fixed paraffin-embedded tissue. Fixative should be neutral-buffered formalin. For solid tumor metastatic bone samples, submit a nondecalcified FFPE sample. Decalcified bone biopsies are not acceptable sample types for this test.
Block: Tumor surface area ≥4 mm² and tumor content ≥10%; ≥50% is preferred. See Note.
Unstained Slides: See table below as a guide to the number of slides required to meet the DNA input requirements.
Tumor Content (%)
Number of Slides Needed
(Each slide cut in 10-μM sections)
5 unstained slides and 1 H&E
10 unstained slides and 1 H&E
• Tumor surface areas between 1-4 mm² with ≥10% tumor content are less likely to meet the DNA input requirements.
• Tumor surface areas between 1-4 mm² and <10% tumor or below <1 mm² will be considered QNS for analysis.
• If sending a core biopsy, if tumor is <0.5 cm in length it is less likely to meet the DNA input requirements.
• If sending a cell block aspirate, at least eight tumor cell clusters providing 400 to 800 intact tumor cells is needed, or it is less likely to meet the DNA input requirements.
Causes for Rejection
Tumor block containing insufficient tumor; broken or stained slides; clotted bone marrow; bone marrow specimen more than five days old. Decalcified bone biopsies
Use cold pack for transport. Be sure cold pack is not in direct contact with specimen during transport.
Includes an assessment of ~2700 mutations within 50 common oncogenes and tumor suppressor genes. Included in the panel are: Genes and their associated variations that are biomarkers for therapies targeting genetic alterations in human cancers; Genes focused on cancer signaling pathways (driver mutations); Genes known to have clinical relevance across multiple tumor types
IntelliGEN® is a next-generation sequencing (NGS) panel that contains ~2600 mutations within 50 common oncogenes and tumor suppressor genes. The information provided in this analysis may assist in making cancer treatment decisions involving target therapies and other therapeutic indications related to the molecular alterations detected in the tumor sample.
This panel targets 50 genes and a fixed set of mutations. Samples with results reported as "no mutation detected" may harbor mutations that are not detected by the assay. Detection of mutation is dependent on sample integrity and the amount of amplifiable DNA present in the specimen. The methods used in this assay are highly selective and, depending on the total amount of DNA present, can detect approximately 5% of mutant DNA in a backgound of wild-type genomic DNA.
Genes assessed in this "hot-spot" panel may harbor mutations not detected by this assay. This assay will not detect gene rearrangements or amplifications. This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the US Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. Results of this test are for investigational purposes only. The result should not be used as a diagnostic procedure without confirmation of the diagnosis by another medically diagnostic product or procedure.
Oncology Therapeutic Panel
Beadling C, Neff TL, Heinrich MC, et al. Combining highly multiplexed PCR with semiconductor-based sequencing for rapid cancer genotyping. J Mol Diagn. 2013 Mar; 15(2):171-176. PubMed 23274167
Merriman B; Ion Torrent R&D Team, Rothberg JM. Progress in ion torrent semiconductor chip based sequencing. Electrophoresis. 2012 Dec; 33(23):3397-3417. Erratum: 2013 Feb; 34(4):619. PubMed 23208921